Dendreon Corp fka DNDNQ

[poorgradstudent]

Sam:

You mentioned on the other board about how the trp program was a big deal for you in regards to dndn's pipeline. I've heard one of the world leaders in TRP research (if not THE leader) talk and express the opinion that he doesn't yet have a handle on the realistic prospects of targeting these channels with drugs.

So if he is currently lukewarm to the idea, I don't think DNDN investors should be ascribing much value to the program. Perhaps DNA returning... err... DNDN reacquiring full rights to the program is a validation of this scientist's comments?

In reading the transcript, I'm also noticing that management is specific that the CMC section will be complete by the end of this year. Are they purposefully refraining from saying "BLA" will be complete? Or is the CMC completion considered synonymous with BLA completion at this stage?